Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKinsey
Boehringer Ingelheim
Baxter
Medtronic

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR ONDANSETRON


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Ondansetron

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00124787 ↗ A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis Completed Canadian Association of Emergency Physicians Phase 4 2005-04-01 Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
OTC NCT00124787 ↗ A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis Completed St. Justine's Hospital Phase 4 2005-04-01 Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
OTC NCT01691690 ↗ Analgesic Effect of IV Acetaminophen in Tonsillectomies Completed Nationwide Children's Hospital Phase 2 2012-10-01 Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial and include central inhibition of the cyclo-oxygenase (COX) enzyme leading to decreased production of prostaglandins from arachidonic acid, interference with serotonergic descending pain pathways, indirect activation of cannabinoid 1 (CB1) receptors and inhibition of nitric oxide pathways through N-methyl-D-aspartate (NMDA) or substance P. Of the above mechanisms, the most commonly known is that of central inhibition of COX enzymes by which the decreased production of prostaglandins diminish the release of excitatory transmitters of substance P and glutamate which are both involved in nociceptive transmission (Anderson, 2008; Smith, 2011). To date, several studies have shown acetaminophen's opioid sparing effect in the pediatric population when given by the rectal or intravenous routes (Korpela et al, 1999; Dashti et al, 2009; Hong et al, 2010).
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Ondansetron

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000289 ↗ Role of Metabolites in Nicotine Dependence (3) - 6 Completed University of Minnesota Phase 2 1998-05-01 The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000289 ↗ Role of Metabolites in Nicotine Dependence (3) - 6 Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 1998-05-01 The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000289 ↗ Role of Metabolites in Nicotine Dependence (3) - 6 Completed National Institute on Drug Abuse (NIDA) Phase 2 1998-05-01 The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000443 ↗ Ondansetron Treatment for Alcoholism Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 The purpose of this study is to: a) evaluate the effectiveness of ondansetron (Zofran) in the treatment of alcohol dependent patients; b) investigate whether early versus late onset alcoholism predicts treatment outcome; and c) determine whether the early and late onset groups respond differently to treatment. Individuals will be "typed" into early onset and late onset alcoholism groups. Individuals will be randomly assigned to a 12-week outpatient treatment program.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ondansetron

Condition Name

Condition Name for Ondansetron
Intervention Trials
Postoperative Nausea and Vomiting 57
Nausea 40
Vomiting 37
Postoperative Pain 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ondansetron
Intervention Trials
Vomiting 196
Nausea 150
Postoperative Nausea and Vomiting 94
Pain, Postoperative 58
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ondansetron

Trials by Country

Trials by Country for Ondansetron
Location Trials
United States 544
Canada 85
Italy 38
Egypt 31
Germany 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ondansetron
Location Trials
Texas 55
California 35
New York 35
North Carolina 27
Illinois 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ondansetron

Clinical Trial Phase

Clinical Trial Phase for Ondansetron
Clinical Trial Phase Trials
Phase 4 154
Phase 3 81
Phase 2/Phase 3 11
[disabled in preview] 109
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ondansetron
Clinical Trial Phase Trials
Completed 342
Recruiting 69
Unknown status 58
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ondansetron

Sponsor Name

Sponsor Name for Ondansetron
Sponsor Trials
Merck Sharp & Dohme Corp. 30
GlaxoSmithKline 14
M.D. Anderson Cancer Center 13
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ondansetron
Sponsor Trials
Other 688
Industry 139
NIH 36
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Dow
Harvard Business School
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.